At 01:04 pm, the biotech sector’s summary was somewhat like this:

• ZIOPHARM Oncology Inc (NASDAQ:ZIOP), is the top gainer of the healthcare sector for the current trading session, and added 7.41% to the share.
• Seattle Genetics, Inc (NASDAQ:SGEN), is among the top loser of the sector, losing -4.81% from the share, and is now trading at $30.89.
• Pfizer Inc (NYSE:PFE), recently hits new 52-week high of $30.48, and is now trading at $34.30, is the most active stock for the session, now gaining volume of 15.38M.
• Delcath Systems, Inc (NASDAQ:DCTH), recently hits new 52-week low of $0.98, and is now trading at $1.05.
• Exelixis, Inc (NASDAQ:EXEL), is the most volatile stock in the meantime, and it remained 8.46% volatile for the week and 8.14% for the month.
• Nanosphere, Inc (NASDAQ:NSPH), will release their earning report, after the market close today.

Insights about some real gainers from healthcare sector, in the course of Wednesday’s current trading session are depicted underneath:

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), traded in a 52-week range of $1.46 to $4.00, hitting new 52-week high of $4.00, with shares inclined 16.13% at $3.77 in current trade, soon after a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, declared that the company has received formal notification from the Nasdaq Stock Market, indicating that the Company has regained compliance with Listing Rule 5450(b)(1)(A), which requires a minimum of $10,000,000 in stockholders’ equity or maintaining a market value of $50,000,000 or greater for ten successive business days. Nasdaq has determined that Anthera has maintained market value of at least $50,000,000 for the last ten successive business days and as such, the Company has met alternative listing requirements for continued listing.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, counting systemic lupus erythematosus, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), traded in a 52-week range of $2.31 to $9.99, with shares inclined 7.57% at $9.58, hitting new 52-week high of $9.99.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), a biotechnology company, engages in the discovery and development of cancer therapies. The company is employing novel gene expression and control technology to deliver DNA for the treatment of cancer.

Thoratec Corp. (NASDAQ:THOR), climbed 6.92% and is now at $38.93, hitting new 52-week high of $40.25, soon after a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, recently stated its financial results for the fourth quarter of 2014. For the quarter ended January 3, 2015, Thoratec stated proceeds of $128.0 million contrast to proceeds of $128.2 million in the fourth quarter of 2013. Net revenue on a GAAP basis was $11.8 million, or $0.21 per diluted share, contrast with GAAP net revenue of $13.1 million, or $0.23 per diluted share, in the same period a year ago. Non-GAAP net revenue, which is described later in this press release, was $21.4 million, or $0.39 per diluted share, contrast with non-GAAP net revenue of $22.1 million, or $0.38 per diluted share, in the same period a year ago.

Thoratec stated proceeds of $128.0 million in the fourth quarter of 2014 contrast to $128.2 million in the same quarter last year. The fourth quarter of 2014 comprised of the benefit of an extra week, which contributed about $8 million of proceed. The HeartMate product line contributed $112.4 million, while the CentriMag product line contributed $12.6 million.

For the year ended January 3, 2015, Thoratec stated proceeds of $477.6 million, a decrease of five percent contrast to the same period last year. The HeartMate product line contributed $416.0 million to proceeds, while the CentriMag product line contributed $50.0 million.

Thoratec Corp. (NASDAQ:THOR), is a world leader in therapies to address advanced-stage heart failure. The company’s products comprise the HeartMate II® LVAS (Left Ventricular Assist Systems) and Thoratec® VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure.

Zoetis Inc. (NYSE:ZTS), gained nearly 3.44% and is now trading at $45.42, hitting new 52-week high of $46.12, soon after the company engaged in the discovery, development, manufacture, and commercialization of animal health medicines, stated its financial results for the fourth quarter and full year 2014 and updated its guidance for full year 2015. The company stated proceed of $1.3 billion for the fourth quarter of 2014, an raise of 5% from the fourth quarter of 2013; proceed reflected an operational2 raise of 9%, not including the influence of foreign currency.

Key Highlights:

In the fourth quarter of 2014:

• Proceed in the U.S. was $589 million, an raise of 14% contrast to the fourth quarter of 2013. Sales of livestock products grew 19%, led by strong anti-infective sales in cattle. Sales of swine products also saw notable growth as the result of new product introductions. Sales of companion animal products grew 7%, driven by APOQUEL® and other key brands such as CERENIA® and CONVENIA®. Growth was offset by competition to our RIMADYL® franchise and competitive pressure in vaccines and parasiticides.
• Proceed in EuAfME was $294 million, a decrease of 1% on an operational basis contrast to the fourth quarter of 2013. Sales of livestock products declined 3% operationally as gains in swine products were offset by declines in poultry and cattle. Growth in livestock product sales in southern Europe and Germany were offset primarily by sales declines in the UK and France. Overall, emerging markets saw strong livestock product sales, partially offset by a decline in sales in Russia. Companion animal products generated growth of 2% operationally due to strong APOQUEL sales in Germany and the UK, in addition to continued growth across the small animal portfolio of medicines. This growth was tempered by the competitive environment for small animal vaccines in developed markets.

Zoetis Inc. (NYSE:ZTS), engaged in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide.

CVS Health Corporation, (NYSE:CVS), showed a positive movement of 0.84% and is now at $102.53, hitting new 52-week high of $103.29, following the news that a pharmacy innovation company assisting people on their path to better health, declared operating results for the three months and year ended December 31, 2014. Net proceeds for the three months ended December 31, 2014, raised 12.9%, or $4.2 billion to $37.1 billion, up from $32.8 billion in the three months ended December 31, 2013. For the year ended December 31, 2014, total proceed raised 9.9%, or $12.6 billion to $139.4 billion, contrast to $126.8 billion for the year ended December 31, 2013.

Proceeds in the Pharmacy Services Segment raised 21.7% to $23.9 billion in the three months ended December 31, 2014. Proceeds in the Retail Pharmacy Segment raised 2.9% to $17.7 billion in the three months ended December 31, 2014. Same store sales raised 1.6% over the preceding year period, with pharmacy same store sales up 5.5% and front store same store sales down 7.2%.

For the three months ended December 31, 2014, the generic dispensing rate raised about 125 basis points to 82.1% in our Pharmacy Services Segment and raised about 140 basis points to 82.4% in our Retail Pharmacy Segment, contrast to the preceding year.

CVS Health Corporation, (NYSE:CVS), is a pharmacy innovation company assisting people on their path to better health. Through its 7,800 retail pharmacies, more than 900 walk-in medical clinics, a leading pharmacy benefits manager with more than 65 million plan members, and expanding specialty pharmacy services, the Company enables people, businesses and communities to manage health in more affordable, effective ways.